source
- Federal rule forces PBMs to disclose fees and rebates to employersThe Trump administration finalized a regulation that will require pharmacy benefit managers (PBMs) to reveal the various fees and compensation they receive from drugmakers, consultants and other pa…
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…